Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1 2Phase 1/2 1

Status

Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 2

Conditions

Neuroblastoma 2Glioblastoma 1Astrocytoma 1

Interventions

Cyclophosphamide 32Filgrastim 18Irinotecan 15Topotecan 14Temozolomide 13Vincristine 12Peripheral Blood Stem Cell Transplantation 12Granulocyte Colony-Stimulating Factor 12Etoposide 12Melphalan 11fludarabine 10Carboplatin 9dinutuximab 8Isotretinoin 8Interleukin-2 8Busulfan 8humanized 3F8 anti-GD2 monoclonal antibody 7aldesleukin 7Doxorubicin 73-Iodobenzylguanidine 7sargramostim 6fludarabine phosphate 6Vorinostat 6Zoledronic Acid 5Stem Cell Transplantation 5Cisplatin 5etoposide phosphate 4Ipilimumab 4Drug Therapy 4ribociclib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × Neuroblastoma × Eflornithine × Clear all
NCT02030964 2025-02-17

DFMO

New Approaches to Neuroblastoma Therapy Consortium

Phase 1 Completed
30 enrolled
CNS

Neuroblastoma

NCT01059071 2024-08-06

Safety Study for Refractory or Relapsed Neuroblastoma With DFMO Alone and in Combination With Etoposide

Milton S. Hershey Medical Center

Phase 1 Completed
21 enrolled 13 charts
CNS

Neuroblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡